We are live on ! Find out more
ASND icon

Ascendis Pharma A/S
ASND

34 hedge funds and large institutions have $646M invested in Ascendis Pharma A/S in 2017 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 15 increasing their positions, 7 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

114% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 7

10% more capital invested

Capital invested by funds: $585M → $646M (+$60.8M)

7.14% more ownership

Funds ownership: 64.46% → 71.6% (+7.1%)

0% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 6

3% less funds holding

Funds holding: 35 → 34 (-1)

29% less funds holding in top 10

Funds holding in top 10: 7 → 5 (-2)

Holders
34
Holders Change
-1
Holders Change %
-2.86%
% of All Funds
0.85%
Holding in Top 10
5
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-28.57%
% of All Funds
0.12%
New
6
Increased
15
Reduced
7
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
O
OrbiMed
New York
+$17.2M
2
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$14.7M
3
EC
EcoR1 Capital
California
+$12.1M
4
BBA
Baker Bros. Advisors
New York
+$10.6M
5
EAM
Eventide Asset Management
Massachusetts
+$10.4M

Top Sellers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
-$13.5M
2
CAM
Cormorant Asset Management
Massachusetts
-$2.8M
3
SFM
Sphera Funds Management
Israel
-$2.48M
4
FCMI
Foresite Capital Management III
California
-$2.05M
5
EU
Emory University
Georgia
-$633K
Name Holding Trade Value Shares
Change 		Change in
Stake
Geode Capital Management
26
Geode Capital Management
Massachusetts
$546K +$129K +4,869 +33%
California Public Employees Retirement System
27
California Public Employees Retirement System
California
$430K +$410K +15,500 New
TI
28
Trexquant Investment
Connecticut
$244K +$233K +8,800 New
MC
29
Matisse Capital
Oregon
$238K +$227K +8,590 New
Bank of America
30
Bank of America
North Carolina
$134K -$13.8K -523 -10%
Bank of Montreal
31
Bank of Montreal
Ontario, Canada
$126K +$67.1K +2,541 +127%
Wells Fargo
32
Wells Fargo
California
$94K -$45.3K -1,716 -34%
Creative Planning
33
Creative Planning
Kansas
$10K – – –
US Bancorp
34
US Bancorp
Minnesota
$2K – – –
CAM
35
Cormorant Asset Management
Massachusetts
– -$2.8M -100,000 Closed
HCM
36
Highbridge Capital Management
New York
– -$420K -15,000 Closed
AG
37
Aperio Group
California
– -$203K -7,242 Closed
Victory Capital Management
38
Victory Capital Management
Texas
– -$144K -5,158 Closed
TRCT
39
Tower Research Capital (TRC)
New York
– -$29.9K -1,133 Closed
UBS Group
40
UBS Group
Switzerland
– -$27K -959 Closed
1
2

ASND Hedge Fund Activity: Q2 2017 in Review

34 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Ascendis Pharma A/S (ASND) for Q2 2017, worth a combined $646M — up 10% from $585M a quarter earlier.

Fund positioning in ASND was balanced in Q2 2017: 6 funds opened new positions, 6 closed out, 15 added to existing stakes and 7 trimmed.

The largest buyer was OrbiMed, adding an estimated $17.2M. The largest seller was Deerfield Management, cutting an estimated $13.5M.

  • 34 institutional investors held Ascendis Pharma A/S (ASND) as of Q2 2017, down from 35 in Q1 2017.
  • Funds reported $646M of Ascendis Pharma A/S stock for Q2 2017, up 10% quarter-over-quarter.
  • 6 funds opened new Ascendis Pharma A/S positions in Q2 2017 and 6 closed out, a net change of 0 holders.
  • The largest Ascendis Pharma A/S buyer in Q2 2017 was OrbiMed, an estimated $17.2M added.
  • The largest Ascendis Pharma A/S seller in Q2 2017 was Deerfield Management, an estimated $13.5M sold.

Based on aggregated 13F filings for Q2 2017.